CNE100003NL9
CNE100003NL9
BLOOMAGE BIOTECHNOLOGY CORPORAT
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 90/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±40.1% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.4x).
Beta (Market Relation)
0.45x
DefensiveVolatility (5Y p.a.)
40.1% p.a.
5-Year HorizonMax Drawdown (5Y)
-83.0%
5-Year HorizonSharpe Ratio
-0.77
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Stable Long-Term Volatility High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -37.9% |
| 3 Years | 38.8% | -61.3% | -0.73 | -25.8% |
| 5 Years | 40.1% | -83.0% | -0.77 | -29.1% |
| 10 Years | — | — | — | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 72.7 (Elevated multiple compression risk)
Strong cyclicality: The business model is sensitive to economic downturns.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -83.0% in the extended horizon.